Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 24 / Drugs : 24 - (DrugBank : 12) / Drug target genes : 6 - Drug target pathways : 132

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Alpelisib
   Murdoch Childrens Research Institute
      2024   Phase 2   NCT05983159   Australia
Apixaban
   Oslo University Hospital
      2025   Phase 2   NCT06729034   Norway
Bleomycin + fibrovein
   Oslo University Hospital
      2011   Phase 4   NCT01347294   Norway
Bleomycin baxter
   Department of Radiology, Oslo University Hospital, Norway
      2011   Phase 4   EUCTR2011-001455-37-NO   Norway
Dehydrated alcohol (absolute alcohol) BP FOR injection
   ORFAGEN
      2009   Phase 2   EUCTR2009-011276-29-FR   France
Direct puncture repair / ethanol
   Al-Azhar University
      2018   -   NCT05586919   Egypt
Direct puncture repair / polidocanol
   Al-Azhar University
      2018   -   NCT05586919   Egypt
Enalapril
   Oslo University Hospital
      2025   Phase 2   NCT06788314   Norway
Ethanol
   Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital
      2023   Phase 0   ChiCTR2300071751   China
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
      2015   Phase 1 study   ChiCTR-OIB-15007455   China
   Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
      2025   -   ChiCTR2500102907   China
Ethanol 96% GEL
   Orfagen
      2007   Phase 2   NCT00462462   France;United States
Ethanol 98% solution
   Orfagen
      2007   Phase 2   NCT00462462   France;United States
Ethanol BP
   ORFAGEN
      2009   Phase 2   EUCTR2009-011276-29-FR   France
Ethanol GEL
   ORFAGEN
      2009   Phase 2   EUCTR2009-011276-29-FR   France
Ethanol-amine oleate sclerotherapy injection
   Suez Canal University
      2019   -   NCT04930952   Egypt
Ethanolamine oleate
   Danjo Atsushi
      2009   Phase 2   JPRN-jRCTs071180067   -
   Nomura Tadashi
      2021   Phase 3   JPRN-jRCT2051200046   -
Fibrin
   The First Affiliated Hospital of Sun Yat-Sen University
      2022   Phase 2   ChiCTR2100053242   China
Fibrovein
   Department of Radiology, Oslo University Hospital, Norway
      2011   Phase 4   EUCTR2011-001455-37-NO   Norway
L0122
   ORFAGEN
      2009   Phase 2   EUCTR2009-011276-29-FR   France
Mirdametinib
   Murdoch Childrens Research Institute
      2024   Phase 2   NCT05983159   Australia
Polidocanol
   Mori Hiroki
      2024   Phase 2   JPRN-jRCTs031230604   Japan;Non
   Uka Mayu
      2021   -   JPRN-jRCTs061200036   -
Qtorin 3.9% rapamycin anhydrous GEL
   Palvella Therapeutics, Inc.
      2024   Phase 2   NCT06653842   United States
Rapamycin
   Peking Union Medical College Hospital
      2018   Phase 4   NCT03767660   China
Sirolimus
   Children's Hospital Medical Center, Cincinnati
      2009   Phase 2   NCT00975819   United States
   Gifu University Hospital
      2020   Phase 3   JPRN-UMIN000038973   Japan
   Medical University of South Carolina
      2022   Phase 2   NCT04861064   United States
   Shanghai Ninth People's Hospital
      2021   Phase 0   ChiCTR2100052762   China
Trametinib tablet
   Stanford University
      2020   Phase 2   NCT04258046   United States